Abstract
In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Angiotensin-Converting Enzyme 2 / metabolism
-
Antibodies, Neutralizing / immunology
-
Antibodies, Viral / biosynthesis*
-
Antibodies, Viral / immunology
-
Antibody Specificity
-
Antigens, Viral / immunology*
-
BNT162 Vaccine
-
COVID-19 / immunology*
-
COVID-19 Vaccines / adverse effects
-
COVID-19 Vaccines / immunology*
-
Convalescence
-
Coronavirus Nucleocapsid Proteins / immunology*
-
Female
-
Health Personnel
-
Humans
-
Immunization, Secondary / adverse effects
-
Immunoglobulin G / biosynthesis*
-
Immunoglobulin G / immunology
-
Immunoglobulin M / biosynthesis*
-
Immunoglobulin M / immunology
-
Immunologic Memory
-
Male
-
Middle Aged
-
Phosphoproteins / immunology
-
SARS-CoV-2 / immunology*
-
Spike Glycoprotein, Coronavirus / immunology*
-
Symptom Assessment
-
Vaccination
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Antigens, Viral
-
COVID-19 Vaccines
-
Coronavirus Nucleocapsid Proteins
-
Immunoglobulin G
-
Immunoglobulin M
-
Phosphoproteins
-
Spike Glycoprotein, Coronavirus
-
nucleocapsid phosphoprotein, SARS-CoV-2
-
spike protein, SARS-CoV-2
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2
-
BNT162 Vaccine